Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Prakash Krishnan
The current outbreak of COVID‐19 caused by 2019‐nCoV has already taken away plethora of human lives. There is an urgent need for cost effective, available, safe, and effective medicine for fighting this virus. As on date, there is no specific medication available for COVID-19. The bitter taste receptor -TAS2R family (present in human airway smooth muscle) is an important player in host defence mechanisms. Considering the caffeine role as bitter agonists to stimulate the TAS2Rs and to activate host defence mechanisms and to suppress the cytokine storms due to its anti-inflammatory action, caffeine can play as an agent for support therapy in the control of SARS-COV-2. Studies demonstrate that caffeine apart from its role as a central nervous system stimulant has proven the ability as an antiviral agent by its role in inhibiting viral protein synthesis. This article is an approach to attract the attention of caffeine researchers to highlight onto the possibilities and suggest the population with beneficial and accessible remedies.